Summit Therapeutics Inc. (SMMT)
$
25.88
+1.14 (4.40%)
Key metrics
Financial statements
Free cash flow per share
-0.2351
Market cap
19.2 Billion
Price to sales ratio
0
Debt to equity
0.0187
Current ratio
10.6302
Income quality
0.7192
Average inventory
0
ROE
-0.7050
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Summit Therapeutics Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines aimed at treating infectious diseases in the United States and Latin America. The firm has a clinical program primarily dedicated to combating Clostridioides difficile infection (CDI), with ridinilazole as its lead product candidate. This orally administered small molecule antibiotic is currently in Phase III clinical trials for CDI treatment. In addition to ridinilazole, Summit Therapeutics offers SMT-738, targeting multidrug-resistant infections, particularly those caused by carbapenem-resistant Enterobacteriaceae, as well as the DDS-04 series designed for the potential treatment of Enterobacteriaceae-related infections. Despite its innovative advancements, the company reported a net loss of -$221,315,000.00 indicating challenges in its operations. The gross profit ratio stands at 0.00 showcasing the efficiency of its production and sales processes. Moreover, the EBITDA ratio of 0.00 highlights operational efficiency, even as the company faces selling, general, and administrative expenses of $48,345,000.00 reflecting its operational overhead costs. The company’s stock is traded under the symbol 'SMMT' in the market, providing investors with insight into its financial performance. The stock is affordable at $25.88 catering to budget-conscious investors who are looking for opportunities in the biopharmaceutical space. Additionally, the stock enjoys a high average trading volume of 5,083,786.00 which indicates strong liquidity and investor interest. With a mid-range market capitalization of $19,220,193,492.00 the company is regarded as a steady performer within its sector. As a key player in the Biotechnology industry, Summit Therapeutics contributes significantly to the overall market landscape, driving innovation and growth. Belonging to the Healthcare sector, it plays a crucial role in advancing solutions to pressing health challenges, continuing to pave the way for new treatments amid its ongoing clinical trials and research initiatives.
Is Summit Therapeutics Inc. (SMMT) a good investment?
Investing in Summit Therapeutics Inc. (SMMT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Summit Therapeutics Inc. (SMMT)'s stock forecast?
Analysts predict Summit Therapeutics Inc. stock to fluctuate between $8.36 (low) and $36.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Summit Therapeutics Inc.'s market capitalization?
As of 2025-07-10, Summit Therapeutics Inc.'s market cap is $19,220,193,492, based on 742,665,900 outstanding shares.
How does Summit Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Summit Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Summit Therapeutics Inc. (SMMT) stock?
To buy Summit Therapeutics Inc. (SMMT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SMMT. Place an order (Market, Limit, etc.).
What is the best time to invest in Summit Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Summit Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.31 | Growth: -68.69%.
Where can I find Summit Therapeutics Inc.'s investor relations reports?
Visit https://www.summittxinc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Summit Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Summit Therapeutics Inc. stock?
All-time high: $36.91 (2025-04-24) | All-time low: $0.66 (2022-12-02).
What are the key trends affecting Summit Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.
fool.com
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal.
globenewswire.com
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
fool.com
An analyst's downbeat new take on Summit Therapeutics (SMMT -11.05%) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absorbed the negative take.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
